NASDAQ$INO
Inovio Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
INOVIO's financial results for Q2 2024 were announced, and recent company developments were updated.
INOVIO reported a net loss of $32.2 million for the second quarter of 2024, with cash, cash equivalents, and short-term investments totaling $110.4 million as of June 30, 2024. The company is facing manufacturing issues with its CELLECTRA® device, delaying the BLA submission for INO-3107 to mid-2025.
- INOVIO anticipates submitting its BLA for INO-3107 in mid-2025 due to device manufacturing issues.
- Phase 3 clinical plans for INO-3112 were submitted to European regulatory authorities.
- INOVIO anticipates resubmitting Phase 2 clinical plans for INO-4201 to the FDA in the third quarter.
- Steve Egge was appointed as Chief Commercial Officer.
Headline financials
Revenue & EPS history
Inovio · Revenue · Quarterly
$101K
Forward guidance
INOVIO estimates its cash runway to extend into the third quarter of 2025, which includes an operational net cash burn estimate of approximately $28 million for the third quarter of 2024.
Tailwinds
- Cash runway extends into the third quarter of 2025.
- Focus on advancing INO-3107 for RRP treatment.
- Plans to submit BLA for INO-3107 remain in place.
- Progress in Phase 3 clinical plans for INO-3112.
- Resubmission of Phase 2 clinical plans for INO-4201 anticipated.
Headwinds
- Manufacturing issue with CELLECTRA® device delaying BLA submission.
- BLA submission for INO-3107 now anticipated in mid-2025.
- Operational net cash burn estimated at $28 million for Q3 2024.
- Uncertainties in clinical trials and product development.
- Dependence on third parties and capital market conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-1.6%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-5.5%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+21.6%
Q4 2014
Best reaction
-27.8%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.3% | -13.5% | — | |
| Q4 2025 | -1.2% | -1.2% | -36.9% | |
| Q3 2025 | -7.1% | -4.7% | -0.9% | |
| Q1 2025 | -1.6% | +7.8% | +4.2% | |
| Q4 2024 | -6.7% | -10.5% | -17.1% | |
| Q3 2024 | -13.9% | -18.6% | -53.1% | |
| Q2 2024 | -1.7% | -8.1% | -26.9% | |
| Q1 2024 | +7.2% | +12.7% | -11.0% | |
| Q4 2023 | -6.7% | +24.4% | +21.9% | |
| Q3 2023 | -7.9% | +0.0% | +0.0% | |
| Q2 2023 | +9.5% | +9.5% | +7.1% | |
| Q1 2023 | -7.1% | -8.3% | -38.1% | |
| Q4 2022 | +3.2% | -4.0% | -34.9% | |
| Q3 2022 | +1.4% | +9.3% | -14.4% | |
| Q2 2022 | +10.2% | +11.4% | -8.5% | |
| Q1 2022 | -23.6% | -16.0% | -30.4% | |
| Q4 2021 | -5.9% | -4.0% | +10.8% | |
| Q3 2021 | +5.6% | +9.1% | -7.0% | |
| Q2 2021 | -5.9% | +1.3% | -9.2% | |
| Q1 2021 | -5.3% | -4.4% | +46.4% | |
| Q4 2020 | -9.7% | -17.2% | -16.4% | |
| Q3 2020 | +9.3% | +6.6% | +8.5% | |
| Q2 2020 | -27.7% | -26.9% | -49.2% | |
| Q1 2020 | +18.8% | +23.7% | +23.3% | |
| Q4 2019 | -14.0% | -12.3% | -3.0% | |
| Q3 2019 | -5.7% | -4.1% | +10.6% | |
| Q2 2019 | -1.6% | -6.3% | -15.8% | |
| Q1 2019 | -4.4% | -9.2% | -37.2% | |
| Q4 2018 | +3.7% | +0.0% | +15.9% | |
| Q3 2018 | +1.1% | -7.5% | -1.3% | |
| Q2 2018 | +14.3% | +13.8% | +35.5% | |
| Q1 2018 | -6.2% | +1.1% | -5.1% | |
| Q4 2017 | +6.6% | +12.6% | +11.5% | |
| Q3 2017 | -16.6% | -14.3% | -15.3% | |
| Q2 2017 | -0.2% | -1.4% | +7.8% | |
| Q1 2017 | +5.8% | +15.2% | +27.0% | |
| Q4 2016 | -6.1% | -7.7% | -7.9% | |
| Q3 2016 | +18.7% | +26.8% | +8.7% | |
| Q2 2016 | -8.1% | -9.1% | -8.1% | |
| Q1 2016 | +4.7% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | +3.1% | — | — | |
| Q2 2015 | +20.5% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | +21.6% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q2 2014 | -12.9% | — | — | |
| Q1 2014 | +2.8% | — | — | |
| Q4 2013 | -2.0% | — | — | |
| Q3 2013 | -1.1% | — | — | |
| Q2 2013 | -27.8% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | -7.6% | — | — | |
| Q2 2012 | +1.9% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -6.5% | — | — | |
| Q3 2011 | -4.8% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -1.8% | — | — | |
| Q3 2010 | +5.9% | — | — | |
| Q2 2010 | -1.1% | — | — | |
| Q1 2010 | -7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro